After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen's osteoporosis and bone-related cancer drug denosumab may be one of the most eagerly-anticipated approvals of the year - not least by Amgen itself, whose future growth depends almost entirely on an FDA nod. But in another sense this antibody marks an ending, not a beginning